Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alra Labs acquires former SKB generics

Executive Summary

The generic manufacturer acquired from Rochester, New York-based Banmax 12 generic prescription drugs and two OTC products that were originally manufactured by SmithKline Beecham Labs. Banmax purchased the drugs from SKB in October 1987 to set the foundation for its generics business. The generic line includes impiramine tabs, propoxyphene caps, propoxyphene compound, tolbutamide, acetazolamide, amitriptyline tabs, and mepromabate. Amitriptyline and meprobamate still need to be approved, and Alra has asked FDA to waive the need for bioequivalence studies for them. Alra will manufacture and market the drugs. With the acquisition, Alra will have a total of 25 drug products. The firm had 1989 sales in the range of $25-$30 mil.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel